Pfizer’s shares sank significantly on Tuesday as global markets climbed higher. Analysts cut their ratings on the firm over no clear growth drivers. Some investors worry the pipeline lacks depth and leadership stays uncertain.
But Pfizer secured a key approval: the first CDK4/6 maintenance therapy for advanced HER2-positive breast cancer. However, the stock losses overshadowed the good news. Offices in Midtown Manhattan evacuated after beams cracked, triggering collapse concerns.